Search Results

• • 24 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

  Authors:Oliver Sartor, Johann de Bono, Kim N. Chi, Karim Fizazi, Ken Herrmann, Kambiz Rahbar, et al.From:The New England Journal of Medicine (Vol. 385, Issue 12) Peer-Reviewed

  Sept. 16, 202126 words Report

   Citation Only

• Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma

  Authors:Karim Fizazi, Isabelle Cojean, Jean-Pierre Pignon, Olivier Rixe, Michel Gatineau, Souad Hadef, et al.From:Cancer (Vol. 82, Issue 6) Peer-Reviewed

  Mar. 15, 1998 Article

   Citation Only

• Advanced seminoma-treatment results and prognostic factors for survival after firat-line, cisplatin-based chemotherapy and for patients with recurrent disease

  Authors:Dany Gholam, Karim Fizazi, Marie-Jose Terrier-Lacombe, Pascale Jan, Stephane Culine, and Christine TheodoreFrom:Cancer (Vol. 98, Issue 4) Peer-Reviewed

  Aug. 15, 2003 Article

   Citation Only

• Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone

  Authors:Joel B. Nelson, Martin Gleave, Kristine Pemberton, Stuart McIntosh, Thomas Morris, Hideyuki Akaza, et al.From:Cancer (Vol. 118, Issue 22) Peer-Reviewed

  Nov. 15, 2012 Clinical report

   Citation Only

• Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

  Authors:Matthew R Smith, Fred Saad, Robert Coleman, Neal Shore, Karim Fizazi, Bertrand Tombal, et al.From:The Lancet (Vol. 379, Issue 9810) Peer-Reviewed

  Jan. 7, 2012 Author abstract, Rep...

   Citation Only

• Abiraterone and increased survival in metastatic prostrate cancer

  Authors:Johann S. de Bono, Christopher J. Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, et al.From:The New England Journal of Medicine (Vol. 364, Issue 21) Peer-Reviewed

  May 26, 201145 words Clinical report

   Citation Only

• Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.

  Authors:Ronald de Wit, Johann de Bono, Cora N. Sternberg, Karim Fizazi, Bertrand Tombal, Christian Wulfing, et al.From:The New England Journal of Medicine (Vol. 381, Issue 26) Peer-Reviewed

  Dec. 26, 201951 words Report

   Citation Only

• A phase ll study of irinotecan in patients with advanced renal cell carcinoma

  Authors:Karim Fizazi, Frederic Rolland, Christine Chevreau, Jean-Pierre Droz, Dominique Mery-Mignard, Stephane Culine, et al.From:Cancer (Vol. 98, Issue 1) Peer-Reviewed

  July 1, 2003 Article

   Citation Only

• Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

  Authors:Karim Fizazi, Neal Shore, Teuvo L. Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, et al.From:The New England Journal of Medicine (Vol. 380, Issue 13) Peer-Reviewed

  Mar. 28, 201941 words Report

   Citation Only

• Abiraterone in metastatic prostate cancer without previous chemotherapy

  Authors:Charles J. Ryan, Matthew R. Smith, Johann S. de Bono, Arturo Molina, Christopher J. Logothetis, Paul de Souza, et al.From:The New England Journal of Medicine (Vol. 368, Issue 2) Peer-Reviewed

  Jan. 10, 201345 words Clinical report

   Citation Only

• Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

  Authors:Karim Fizazi, Michael Carducci, Matthew Smith, Ronaldo Damião, Janet Brown, Lawrence Karsh, et al.From:The Lancet (Vol. 377, Issue 9768) Peer-Reviewed

  Mar. 5, 2011565 words Clinical report

   Abstract Only

• Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors

  Authors:Jorg T. Hartmann, Sophie D. Fossa, Craig R. Nichols, Jean-Paul Droz, Alan Horwich, Arthur Gerl, et al.From:Journal of the National Cancer Institute (Vol. 93, Issue 22) Peer-Reviewed

  Nov. 21, 2001340 words Article

   Abstract Only

• Enzalutamide in Men with Nonmetastatic, castration-Resistant Prostate Cancer

  Authors:Maha Hussain, Karim Fizazi, Fred Saad, Per Rathenborg, Neal Shore, Ubirajara Ferreira, et al.From:The New England Journal of Medicine (Vol. 378, Issue 26) Peer-Reviewed

  June 28, 201850 words Report

   Citation Only

• Olaparib for Metastatic Castration-Resistant Prostate Cancer.

  Authors:Johann De Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, et al.From:The New England Journal of Medicine (Vol. 382, Issue 22) Peer-Reviewed

  May 28, 202050 words Report

   Citation Only

• Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.

  Authors:Cora N. Sternberg, Karim Fizazi, Fred Saad, Neal D. Shore, Ugo De Giorgi, David F. Penson, et al.From:The New England Journal of Medicine (Vol. 382, Issue 23) Peer-Reviewed

  June 4, 202055 words Report

   Citation Only

• Increased survival with enzalutamide in prostate cancer after chemotherapy

  Authors:Howard I. Scher, Kurt Miller, Andrew J. Armstrong, Mark Fleming, Lynn Seely, Karim Fizazi, et al.From:The New England Journal of Medicine (Vol. 367, Issue 13) Peer-Reviewed

  Sept. 27, 201277 words Clinical report

   Citation Only

• Sequential therapy in renal cell carcinoma

  Authors:Bernard Escudier, Marine Gross Goupil, Christophe Massard, and Karim FizaziFrom:Cancer (Vol. 115, Issue 10) Peer-Reviewed

  May 15, 2009 Conference notes

   Citation Only

• Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

  Authors:Maha Hussain, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, et al.From:The New England Journal of Medicine (Vol. 383, Issue 24) Peer-Reviewed

  Dec. 10, 202052 words Report

   Citation Only

• Meningeal carcinomatosis in patients with breast carcinoma: clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen

  Authors:Karim Fizazi, Bernard Asselain, Anne Vincent-Salomon, Michel Jouve, Veronique Dieras, Thao Palangie, et al.From:Cancer (Vol. 77, Issue 7) Peer-Reviewed

  Apr. 1, 1996 Article

   Citation Only

• Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.

  Authors:Karim Fizazi, Neal Shore, Teuvo L. Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, et al.From:The New England Journal of Medicine (Vol. 383, Issue 11) Peer-Reviewed

  Sept. 10, 202042 words Report

   Citation Only